Clinical Trial: Hyper-CVAD Treatment in Lymphoblastic Lymphoma
Study Status: Terminated
Recruit Status: Unknown status
Study Type: Observational
Official Title: The Clinical Outcomes of Hyper-CVAD Treatment in Lymphoblastic Lymphoma
Brief Summary: Treatment outcomes of lymphoblastic lymphoma (LBL) have improved by the use of the regimens for acute lymphoblastic leukemia. Hyper-CVAD is one of the most effective treatments with high remission rate in acute lymphoblastic leukemia (ALL) and LBL. However, the treatment outcome of hyper-CVAD in LBL has reported only in small number of patients from single institution. The investigators conducted this study to evaluate the hyper-CVAD regimen based treatment in LBL.
Detailed Summary: We will analyze treatment outcome of lymphoblastic lymphoma patients treated with hyper-CVAD regimen from 13 institutions in Korea. In all patients, hyper-CVAD was initial treatment. After achievement of response, patients either underwent hematopoietic stem cell transplantation (HSCT) or consolidation with hyper-CVAD.
Sponsor: Ajou University School of Medicine
Current Primary Outcome:
- Overall survival [ Time Frame: 3-year ]
- Progression free survival [ Time Frame: 3-year ]
Original Primary Outcome: Same as current
Current Secondary Outcome: Response Rate [ Time Frame: 24 weeks ]
Original Secondary Outcome: Same as current
Information By: Ajou University School of Medicine
Dates:
Date Received: March 13, 2013
Date Started: January 2012
Date Completion:
Last Updated: March 14, 2013
Last Verified: March 2013
